Price Chart
Key Statistics
Market Cap(EOD)886.84M
Enterprise Value811.96M
P/E Ratio (TTM)-10.52
P/B Ratio (TTM)3.57
P/S Ratio (TTM)5.39
Earnings Yield (TTM)-9.50%
ROE (TTM)-31.99%
ROIC (TTM)-17.36%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.01
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.